TY - JOUR
T1 - Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death
AU - Klemke, Claus Detlev
AU - Brenner, Dirk
AU - Weiß, Eva Maria
AU - Schmidt, Marc
AU - Leverkus, Martin
AU - Gülow, Karsten
AU - Krammer, Peter H.
PY - 2009/5/15
Y1 - 2009/5/15
N2 - Restimulation of previously activated T cells via the T-cell receptor (TCR) leads to activation-induced cell death (AICD), which is, at least in part, dependent on the death receptor CD95 (APO-1, FAS) and its natural ligand (CD95L). Here, we characterize cutaneous T-cell lymphoma (CTCL) cells (CTCL tumor cell lines and primary CTCL tumor cells from CTCL patients) as AICD resistant. We show that CTCL cells have elevated levels of the CD95-inhibitory protein cFLIP. However, cFLIPis not responsible for CTCL AICD resistance. Instead, our data suggest that reduced TCR-proximal signaling in CTCL cells is responsible for the observed AICD resistance. CTCL cells exhibit no PLC-γ1 activity, resulting in an impaired Ca2+ release and reduced generation of reactive oxygen species upon TCR stimulation. Ca2+ and ROS production are crucial for up-regulation of CD95L and reconstitution of both signals resulted in AICD sensitivity of CTCL cells. In accordance with these data, CTCL tumor cells from patients with Sézary syndrome do not up-regulate CD95L upon TCR-stimulation and are therefore resistant to AICD. These results show a novel mechanism of AICD resistance in CTCL that could have future therapeutic implications to overcome apoptosis resistance in CTCL patients.
AB - Restimulation of previously activated T cells via the T-cell receptor (TCR) leads to activation-induced cell death (AICD), which is, at least in part, dependent on the death receptor CD95 (APO-1, FAS) and its natural ligand (CD95L). Here, we characterize cutaneous T-cell lymphoma (CTCL) cells (CTCL tumor cell lines and primary CTCL tumor cells from CTCL patients) as AICD resistant. We show that CTCL cells have elevated levels of the CD95-inhibitory protein cFLIP. However, cFLIPis not responsible for CTCL AICD resistance. Instead, our data suggest that reduced TCR-proximal signaling in CTCL cells is responsible for the observed AICD resistance. CTCL cells exhibit no PLC-γ1 activity, resulting in an impaired Ca2+ release and reduced generation of reactive oxygen species upon TCR stimulation. Ca2+ and ROS production are crucial for up-regulation of CD95L and reconstitution of both signals resulted in AICD sensitivity of CTCL cells. In accordance with these data, CTCL tumor cells from patients with Sézary syndrome do not up-regulate CD95L upon TCR-stimulation and are therefore resistant to AICD. These results show a novel mechanism of AICD resistance in CTCL that could have future therapeutic implications to overcome apoptosis resistance in CTCL patients.
UR - http://www.scopus.com/inward/record.url?scp=66249137475&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-08-4631
DO - 10.1158/0008-5472.CAN-08-4631
M3 - Article
C2 - 19435902
AN - SCOPUS:66249137475
SN - 0008-5472
VL - 69
SP - 4175
EP - 4183
JO - Cancer Research
JF - Cancer Research
IS - 10
ER -